000292528 001__ 292528
000292528 005__ 20250731110122.0
000292528 0247_ $$2doi$$a10.1002/ijc.35152
000292528 0247_ $$2pmid$$apmid:39212345
000292528 0247_ $$2ISSN$$a0020-7136
000292528 0247_ $$2ISSN$$a1097-0215
000292528 0247_ $$2altmetric$$aaltmetric:167057187
000292528 037__ $$aDKFZ-2024-01774
000292528 041__ $$aEnglish
000292528 082__ $$a610
000292528 1001_ $$0P:(DE-He78)a8ba894a47d332308575c75acc0e80df$$aJanke, Florian$$b0$$eFirst author$$udkfz
000292528 245__ $$aEarly circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy.
000292528 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000292528 3367_ $$2DRIVER$$aarticle
000292528 3367_ $$2DataCite$$aOutput Types/Journal article
000292528 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1735806736_23499
000292528 3367_ $$2BibTeX$$aARTICLE
000292528 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292528 3367_ $$00$$2EndNote$$aJournal Article
000292528 500__ $$a#EA:B063#EA:E050#LA:B063#LA:E050# / 2025 Feb 15;156(4):853-864
000292528 520__ $$aLocal recurrence after radiotherapy is common in locally advanced head and neck cancer (HNC) patients. Re-irradiation can improve local disease control, but disease progression remains frequent. Hence, predictive biomarkers are needed to adapt treatment intensity to the patient's individual risk. We quantified circulating tumor DNA (ctDNA) in sequential plasma samples and correlated ctDNA levels with disease outcome. Ninety four longitudinal plasma samples from 16 locally advanced HNC patients and 57 healthy donors were collected at re-radiotherapy baseline, after 5 and 10 radiation fractions, at irradiation end, and at routine follow-up visits. Plasma DNA was subjected to low coverage whole genome sequencing for copy number variation (CNV) profiling to quantify ctDNA burden. CNV-based ctDNA burden was detected in 8/16 patients and 25/94 plasma samples. Ten additional ctDNA-positive samples were identified by tracking patient-specific CNVs found in earlier sequential plasma samples. ctDNA-positivity after 5 and 10 radiation fractions (both: log-rank, p = .050) as well as at the end of irradiation correlated with short progression-free survival (log-rank, p = .006). Moreover, a pronounced decrease of ctDNA toward re-radiotherapy termination was associated with worse treatment outcome (log-rank, p = .005). Dynamic ctDNA tracking in serial plasma beyond re-radiotherapy reflected treatment response and imminent disease progression. In five patients, molecular progression was detected prior to tumor progression based on clinical imaging. Our findings emphasize that quantifying ctDNA during re-radiotherapy may contribute to disease monitoring and personalization of adjuvant treatment, follow-up intervals, and dose prescription.
000292528 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000292528 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292528 650_7 $$2Other$$acirculating tumor DNA
000292528 650_7 $$2Other$$acopy number variations
000292528 650_7 $$2Other$$ahead and neck cancer
000292528 650_7 $$2Other$$apredictive biomarker
000292528 650_7 $$2Other$$are‐radiotherapy
000292528 7001_ $$0P:(DE-HGF)0$$aStritzke, Florian$$b1$$eFirst author
000292528 7001_ $$aDvornikovich, Katharina$$b2
000292528 7001_ $$aFranke, Henrik$$b3
000292528 7001_ $$0P:(DE-He78)76bfaf88ae4d178d004bad31146faeed$$aAngeles, Arlou Kristina$$b4$$udkfz
000292528 7001_ $$0P:(DE-He78)21deedf68828db11fadcdd122cf860da$$aRiediger, Anja Lisa$$b5$$udkfz
000292528 7001_ $$0P:(DE-He78)1b8a6fad553f26145f0530d5358fcd64$$aOgrodnik, Simon$$b6$$udkfz
000292528 7001_ $$0P:(DE-He78)96b19c8b439a3de426cef280bbbc0609$$aGerhardt, Sabrina$$b7$$udkfz
000292528 7001_ $$aRegnery, Sebastian$$b8
000292528 7001_ $$aSchröter, Philipp$$b9
000292528 7001_ $$aBauer, Lukas$$b10
000292528 7001_ $$aWeusthof, Katharina$$b11
000292528 7001_ $$0P:(DE-He78)0f26d76d27427945f14f0e874d824aa6$$aGörtz, Magdalena$$b12$$udkfz
000292528 7001_ $$0P:(DE-HGF)0$$aHarrabi, Semi$$b13
000292528 7001_ $$0P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aHerfarth, Klaus$$b14
000292528 7001_ $$0P:(DE-He78)2af28acfaad8f466abb166306f9597bd$$aNeelsen, Christian$$b15$$udkfz
000292528 7001_ $$0P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aPaech, Daniel$$b16$$udkfz
000292528 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b17$$udkfz
000292528 7001_ $$0P:(DE-He78)360c5bc2b71a849e35aca747c041dda7$$aAbdollahi, Amir$$b18$$udkfz
000292528 7001_ $$0P:(DE-HGF)0$$aAdeberg, Sebastian$$b19
000292528 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b20$$udkfz
000292528 7001_ $$0P:(DE-He78)7483734fd8ab316391aa604c95f0e98a$$aSültmann, Holger$$b21$$eLast author$$udkfz
000292528 7001_ $$0P:(DE-He78)cbbd83b83a83176c38ba2c45ac072a3d$$aHeld, Thomas$$b22$$eLast author
000292528 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35152$$gp. ijc.35152$$n4$$p853-864$$tInternational journal of cancer$$v156$$x0020-7136$$y2025
000292528 8564_ $$uhttps://inrepo02.dkfz.de/record/292528/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Janke%20-%20Early%20circulating%20tumor%20DNA%20changes%20predict%20outcomes%20in%20head%20and%20neck%20cancer.pdf
000292528 8564_ $$uhttps://inrepo02.dkfz.de/record/292528/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Janke%20-%20Early%20circulating%20tumor%20DNA%20changes%20predict%20outcomes%20in%20head%20and%20neck%20cancer.pdf?subformat=pdfa$$xpdfa
000292528 909CO $$ooai:inrepo02.dkfz.de:292528$$pVDB
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8ba894a47d332308575c75acc0e80df$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)76bfaf88ae4d178d004bad31146faeed$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)21deedf68828db11fadcdd122cf860da$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1b8a6fad553f26145f0530d5358fcd64$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)96b19c8b439a3de426cef280bbbc0609$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f26d76d27427945f14f0e874d824aa6$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2af28acfaad8f466abb166306f9597bd$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)360c5bc2b71a849e35aca747c041dda7$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7483734fd8ab316391aa604c95f0e98a$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000292528 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cbbd83b83a83176c38ba2c45ac072a3d$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000292528 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000292528 9141_ $$y2024
000292528 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000292528 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000292528 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000292528 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000292528 9202_ $$0I:(DE-He78)B063-20160331$$kB063$$lB063 Krebsgenomforschung$$x0
000292528 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000292528 9201_ $$0I:(DE-He78)B063-20160331$$kB063$$lB063 Krebsgenomforschung$$x0
000292528 9201_ $$0I:(DE-He78)E250-20160331$$kE250$$lNWG KKE Multiparametrische Methoden zur Früherkennung des Prostatakarzinoms$$x1
000292528 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x2
000292528 9201_ $$0I:(DE-He78)E210-20160331$$kE210$$lE210 KKE Translationale Radioonkologie$$x3
000292528 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x4
000292528 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x5
000292528 9200_ $$0I:(DE-He78)B063-20160331$$kB063$$lB063 Krebsgenomforschung$$x0
000292528 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000292528 980__ $$ajournal
000292528 980__ $$aVDB
000292528 980__ $$aI:(DE-He78)B063-20160331
000292528 980__ $$aI:(DE-He78)E250-20160331
000292528 980__ $$aI:(DE-He78)E050-20160331
000292528 980__ $$aI:(DE-He78)E210-20160331
000292528 980__ $$aI:(DE-He78)HD01-20160331
000292528 980__ $$aI:(DE-He78)E010-20160331
000292528 980__ $$aUNRESTRICTED